Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised…

By J. Paavonen, P. Naud, J. Salmerón, C. Wheeler, S. Chow, D. Apter, H. Kitchener, X. Castellsagué, J. Teixeira, S. Skinner and 17 more. The Lancet, 2009

1,578 citations recorded by the source corpus.

Subfields: Epidemiology, Microbiology, Otorhinolaryngology

View Paper: https://www.semanticscholar.org/paper/9fbaa55086501bd2bcf06edafa0583869d606e62

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. A. Jemal
2. S. Plotkin
3. R. Siegel

Citations in the corpus

• Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer—systematic review and meta‐analysis of trends by time and region (2013, background): “Data were collected on study and sample characteristics, country, and time period of collection of study sample, the primary sites included, type of sample used (fresh-frozen or formalin-fixed paraffin-embedded), type of HPV assay used, and the proportion that tested positive for HPV and for HPV-16.”
• Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. (2013, background): “Two prophylactic human papillomavirus (HPV) vaccines are available and have been shown in clinical trials to have high efficacy for prevention of infection and associated disease due to HPV types targeted by the vaccine [1, 2].”
• Correlates of Protection Induced by Vaccination (2010, background): “However, in animal models of vaccination, passive antibody is sufficient for protection (18, 50, 171, 177), and the high level of vaccine efficacy against infection in humans suggests that antibody is the effector mechanism (51, 123).”
• Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels (2013, positive): “Data from clinical trials have shown that both vaccines prevent vaccine type–related cervical precancers (22,23); the quadrivalent vaccine has been shown to also prevent vaginal, vulvar, and anal precancers (24,25).”